Table 4 CI surgery in 10 patients with MYH9 -RD
From: Cochlear implantation is safe and effective in patients with MYH9-related disease
Patient/family | CI side | Surgical approach1 | Device | Prophylaxis for bleeding | Intraoperative bleeding2 | Postoperative bleeding |
|---|---|---|---|---|---|---|
1/1 | R | Round window | Digisonic SP (Neurelec) | Platelet apheresis, 1U pre + 1U post | 1 | None |
2/2 | R | Round window | Nucleus CI24RE (Cochlear) | Platelet apheresis, 1U pre | 3 | None |
3/3 | L | Round window | Maestro Concerto Flex 28 (Med-el) | Platelet apheresis, 1U pre + 1U post | 1 | None |
4/4 | R | Round window | Nucleus Freedom CI24RE (Cochlear) | None | 1 | None |
5/5 | L + R | Cochleostomy | Nucleus Mini22 (Cochlear) | nd | 1 | None |
6/6 | L | Round window | Digisonic SP (Neurelec) | Platelet apheresis, 1U pre phenocompatible | 1 | None |
7/7 | L | Cochleostomy | Nucleus CI512 (Cochlear) | None | 1 | None |
8/7 | R | Cochleostomy | Nucleus CI24R (CA) (Cochlear) | None | 2 | Hematoma at the site of surgical wound |
9/7 | L | Cochleostomy | Mini-system 22 CI22M (Cochlear) | None | 1 | None |
10/8 | R | Round window | Maestro Concerto Flex 28 (Med-el) | Tranexamic acid 1Â g i.v. pre, then 1500Â mg/day p.o. post for 7Â days | 1 | None |